Correction to: From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials.
IF 3.7
2区 医学
Q1 CLINICAL NEUROLOGY
引用次数: 0
更正：从理论到治疗：利用双重M1/M4毒蕈碱受体激动剂xanomeline和trospium氯释放精神分裂症毒蕈碱受体激活的潜力和临床试验的见解。
本文章由计算机程序翻译，如有差异，请以英文原文为准。
求助全文
约1分钟内获得全文
求助全文
来源期刊
CiteScore
8.40
自引率
2.10%
发文量
230
审稿时长
4-8 weeks
期刊介绍：
The central focus of the journal is on research that advances understanding of existing and new neuropsychopharmacological agents including their mode of action and clinical application or provides insights into the biological basis of psychiatric disorders and thereby advances their pharmacological treatment. Such research may derive from the full spectrum of biological and psychological fields of inquiry encompassing classical and novel techniques in neuropsychopharmacology as well as strategies such as neuroimaging, genetics, psychoneuroendocrinology and neuropsychology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
